Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 7,400 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 7,400 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $85.37, for a total value of $631,738.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Elena Ridloff also recently made the following trade(s):

• On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.42, for a total value of $392,932.00.

Kymera Therapeutics Trading Up 0.6%

Kymera Therapeutics stock opened at $85.40 on Friday. The stock has a market cap of $6.97 billion, a PE ratio of -23.21 and a beta of 2.28. The stock has a 50-day moving average price of $81.26 and a 200 day moving average price of $71.73. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same period in the previous year, the firm posted ($0.88) EPS. The company’s revenue for the quarter was down 60.8% compared to the same quarter last year. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on KYMR shares. Barclays upped their price objective on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Morgan Stanley reiterated an “overweight” rating and issued a $123.00 price target on shares of Kymera Therapeutics in a report on Thursday, February 26th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. HC Wainwright raised their price objective on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Stifel Nicolaus set a $114.00 target price on Kymera Therapeutics in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $118.90.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Kymera Therapeutics by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after purchasing an additional 1,833 shares during the period. Millennium Management LLC grew its stake in shares of Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after buying an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Kymera Therapeutics by 343.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 207,722 shares of the company’s stock worth $9,065,000 after buying an additional 160,848 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.